The role of calcium antagonists in patients with chronic renal failure

Karl Heinz Rahn1

  • 1University of Münster Medical School, c/o Potstiege 42, 48161 Münster, Germany. rahn@uni-muenster.de

Insights

For patients with chronic renal failure and high blood pressure, initiating treatment with renin-angiotensin system inhibitors is recommended. These drugs are more effective than calcium antagonists in slowing kidney function decline.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Hypertension is common in chronic renal failure (CRF) and increases cardiovascular risk.
  • Antihypertensive therapy aims to reduce cardiovascular events and slow kidney disease progression.
  • Calcium antagonists are established antihypertensives but may not be optimal for CRF.

Purpose of the Study:

  • To evaluate the efficacy of different antihypertensive drug classes in patients with chronic renal failure.
  • To determine the optimal initial pharmacotherapy for hypertensive patients with CRF.

Main Methods:

  • Review of numerous studies and controlled clinical trials.
  • Comparative analysis of antihypertensive agents, including calcium antagonists and renin-angiotensin system inhibitors.
  • Focus on outcomes related to cardiovascular events and renal function preservation.

Main Results:

  • Calcium antagonists effectively lower blood pressure and prevent cardiovascular complications, similar to other classes.
  • Drugs targeting the renin-angiotensin system (ACE-inhibitors and AT1-antagonists) demonstrate superior efficacy in delaying renal insufficiency progression in CRF patients.
  • ACE-inhibitors and AT1-antagonists show particular benefit in patients with type-2 diabetic nephropathy.

Conclusions:

  • While calcium antagonists are safe and effective for blood pressure control, they are not superior in preventing cardiovascular complications.
  • Renin-angiotensin system inhibitors are more beneficial than other antihypertensive agents for patients with chronic renal failure.
  • Initial antihypertensive treatment for hypertensive patients with CRF should involve a drug that inhibits the renin-angiotensin system.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...